Pfizer-BioNTech抗COVID-19疫苗接种后的即时过敏反应:病例报告

IF 0.2 Q4 RESPIRATORY SYSTEM Current Respiratory Medicine Reviews Pub Date : 2022-09-22 DOI:10.2174/1573398x18666220922101735
Amal Miqdadi, Imad Abousahfa, Mourad Nafaa, Mostapha Noussair, S. Jidane, L. Belyamani
{"title":"Pfizer-BioNTech抗COVID-19疫苗接种后的即时过敏反应:病例报告","authors":"Amal Miqdadi, Imad Abousahfa, Mourad Nafaa, Mostapha Noussair, S. Jidane, L. Belyamani","doi":"10.2174/1573398x18666220922101735","DOIUrl":null,"url":null,"abstract":"\n\nTo date, the vaccine is the only weapon to stop the global pandemic caused by the SARS-CoV-2. But, several clinical cases of complications have been reported in the literature especially allergic reactions.\n\n\n\nWe report a case of 35-year-old woman, known asthmatic with history of a chronic urticaria, an allergic rhinoconjunctivitis and an angioedema after taking NSAIDs. The patient presented 10 minutes after vaccination by Pfizer-BioNTech vaccine, an immediate allergic reaction complicated 12 hours after, by an angioedema.\n\n\n\nDuring the first wave of COVID-19, and after initiation of the vaccination program in Morocco, vaccinating people with severe allergies was not recommended. This reality was changed after the second wave of SARS-CoV-2 Delta, on condition of doing it under medical monitoring. We should propose to all risky persons to take a premedication if needed to avoid such reactions considering the benefits incurred. The use of anti-histamines seems to be necessary. But as in our patient’s case, anti-histamines alone were not sufficient to avoid this local reaction. They probably reduced the intensity of the reaction but did not avoid it. Therefore, we should propose a combination of drugs made by corticosteroids and anti-histamines as a premedication may be a safe alternative to the risky patients and last but not least a close monitoring should be proposed.\n\n\n\nThe main purpose of this case if to raise awareness of this side effect among practitioners and make them capable to managing it correctly.\n","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An immediate allergic reaction following the anti-COVID-19 vaccine Pfizer-BioNTech : A case report\",\"authors\":\"Amal Miqdadi, Imad Abousahfa, Mourad Nafaa, Mostapha Noussair, S. Jidane, L. Belyamani\",\"doi\":\"10.2174/1573398x18666220922101735\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nTo date, the vaccine is the only weapon to stop the global pandemic caused by the SARS-CoV-2. But, several clinical cases of complications have been reported in the literature especially allergic reactions.\\n\\n\\n\\nWe report a case of 35-year-old woman, known asthmatic with history of a chronic urticaria, an allergic rhinoconjunctivitis and an angioedema after taking NSAIDs. The patient presented 10 minutes after vaccination by Pfizer-BioNTech vaccine, an immediate allergic reaction complicated 12 hours after, by an angioedema.\\n\\n\\n\\nDuring the first wave of COVID-19, and after initiation of the vaccination program in Morocco, vaccinating people with severe allergies was not recommended. This reality was changed after the second wave of SARS-CoV-2 Delta, on condition of doing it under medical monitoring. We should propose to all risky persons to take a premedication if needed to avoid such reactions considering the benefits incurred. The use of anti-histamines seems to be necessary. But as in our patient’s case, anti-histamines alone were not sufficient to avoid this local reaction. They probably reduced the intensity of the reaction but did not avoid it. Therefore, we should propose a combination of drugs made by corticosteroids and anti-histamines as a premedication may be a safe alternative to the risky patients and last but not least a close monitoring should be proposed.\\n\\n\\n\\nThe main purpose of this case if to raise awareness of this side effect among practitioners and make them capable to managing it correctly.\\n\",\"PeriodicalId\":44030,\"journal\":{\"name\":\"Current Respiratory Medicine Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Respiratory Medicine Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1573398x18666220922101735\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Respiratory Medicine Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573398x18666220922101735","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

迄今为止,疫苗是阻止严重急性呼吸系统综合征冠状病毒2型引起的全球大流行的唯一武器。但是,文献中已经报道了一些并发症的临床病例,尤其是过敏反应。我们报告一例35岁女性,已知哮喘,有慢性荨麻疹、过敏性鼻结膜炎和服用非甾体抗炎药后血管性水肿病史。该患者在接种辉瑞-BioNTech疫苗10分钟后出现血管性水肿,12小时后立即出现过敏反应。在第一波新冠肺炎期间,以及在摩洛哥启动疫苗接种计划后,不建议为严重过敏人群接种疫苗。这一现实在第二波严重急性呼吸系统综合征冠状病毒2型德尔塔疫情后发生了改变,条件是在医疗监测下进行。考虑到所带来的好处,我们应该建议所有有风险的人在必要时进行药物治疗,以避免这种反应。使用抗组胺药似乎是必要的。但与我们患者的情况一样,单用抗组胺药不足以避免这种局部反应。他们可能降低了反应的强度,但并没有避免。因此,我们应该提出皮质类固醇和抗组胺药的联合用药,作为对高危患者的安全替代方案,最后但并非最不重要的是,应该提出密切监测。本案例的主要目的是提高从业者对这种副作用的认识,并使他们能够正确管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
An immediate allergic reaction following the anti-COVID-19 vaccine Pfizer-BioNTech : A case report
To date, the vaccine is the only weapon to stop the global pandemic caused by the SARS-CoV-2. But, several clinical cases of complications have been reported in the literature especially allergic reactions. We report a case of 35-year-old woman, known asthmatic with history of a chronic urticaria, an allergic rhinoconjunctivitis and an angioedema after taking NSAIDs. The patient presented 10 minutes after vaccination by Pfizer-BioNTech vaccine, an immediate allergic reaction complicated 12 hours after, by an angioedema. During the first wave of COVID-19, and after initiation of the vaccination program in Morocco, vaccinating people with severe allergies was not recommended. This reality was changed after the second wave of SARS-CoV-2 Delta, on condition of doing it under medical monitoring. We should propose to all risky persons to take a premedication if needed to avoid such reactions considering the benefits incurred. The use of anti-histamines seems to be necessary. But as in our patient’s case, anti-histamines alone were not sufficient to avoid this local reaction. They probably reduced the intensity of the reaction but did not avoid it. Therefore, we should propose a combination of drugs made by corticosteroids and anti-histamines as a premedication may be a safe alternative to the risky patients and last but not least a close monitoring should be proposed. The main purpose of this case if to raise awareness of this side effect among practitioners and make them capable to managing it correctly.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
53
期刊介绍: Current Respiratory Medicine Reviews publishes frontier reviews on all the latest advances on respiratory diseases and its related areas e.g. pharmacology, pathogenesis, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in respiratory medicine.
期刊最新文献
Assessing Lung Function and Quality of Life in COVID-19 Patients: A Pilot Study Pulmonary Arterial Hypertension (PAH) Group 1 (Part A): Overview, Classification, Clinical Subsets, and Workup Deteriorating Pulmonary Functions in Patients with Rheumatoid Arthritis- A Pilot Study From South India COVID-19 Vaccines and the Menstrual Cycle: A Cross-Sectional Study NAT2 Gene Variants as a Provocative Factor for the Severe Course of COVID-19 Pneumonia in Ukrainian Patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1